BRCA2 and breast carcinoma: Specifically, Robson et al. [6] have reported that 10-year breast-cancer-specific survival is significantly worse in BRCA1 mutation carriers than that in non-carriers (62% vs. 86%, p < 0.001), but not in BRCA2 mutation carriers (84% vs. 86%, p = 0.76).